KNSAKiniksa Pharmaceuticals International, plc

HealthcareUSD
$77.16

Price

$77.16+129%1Y
1M+0.88%1Y+129%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Average
6/10
Value17
Quality72
Momentum71
Growth83
Strongest Growth, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.
What they do

We are a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Our portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. ARCALYST is an interleukin-1α (“IL-1α”) and interleukin-1β (“IL-1β”) cytokine trap. In 2017, we licensed ARCALYST from Regeneron, which discovered and initially developed the drug.

In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR

P/E (TTM)84.8
Market Cap$4.38B
1Y Return+129%
5Y Return+520%

Kiniksa Pharmaceuticals International, plc (KNSA) reported revenue of $214M in Q1 2026 (quarter ended Mar 31, 2026), up 56% from the same quarter a year earlier. That came with a gross margin of 90% and net income of $23M (11% of revenue). For the full year FY2025, revenue was $678M (+60% year on year) and net income $59M.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Drug Manufacturers - Specialty & Generic

Ranks #10 of 29 by Smart Score

Compare peers
INDV-1.7%
Indivior Pharmaceuticals, Inc.
RGC+0.67%
Regencell Bioscience Holdings Limited
AMRX-2.3%
Amneal Pharmaceuticals, Inc.
LQDA-1.5%
Liquidia Corporation
LNTH-0.53%
Lantheus Holdings, Inc.
SUPN-2.5%
Supernus Pharmaceuticals, Inc.